Cargando…

Serum tumor necrosis factor alpha increased during remission with Etanercept

Detalles Bibliográficos
Autores principales:	Spirchez, Mihaela, Samasca, Gabriel, Bolba, Claudia, Miu, Nicolae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194456/ http://dx.doi.org/10.1186/1546-0096-9-S1-P108

Ejemplares similares

Interleukin-6 overproduction correlates with disease activity and severity in juvenile idiopathic arthritis
por: Spirchez, Mihaela, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept
por: Baraliakos, X, et al.
Publicado: (2005)

Inflence of clinical and genetic characteristics on ability to achive and maintain remission in JIA patients on etanercept treatment
por: Lazarevic, Dragana S, et al.
Publicado: (2014)

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013)

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy
por: Radziszewska, Anna, et al.
Publicado: (2014)

PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
por: Pratsidou-Gertsi, P, et al.
Publicado: (2013)

The adverse drug reactions to tumor necrosis factor alpha inhibitor
por: Park, Hye-Kyung, et al.
Publicado: (2014)

Tumor necrosis factor-alpha polymorphism and susceptibility to juvenile idiopathic arthritis
por: Bayraktar, S, et al.
Publicado: (2008)

T cell contact-mediated induction of tumor necrosis factor alpha in peripheral blood monocytes is inhibited by autologous serum in rheumatoid arthritis
por: Wagner, U, et al.
Publicado: (2003)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Induced myelopathy after long-term anti-tumor necrosis factor alpha treatment
por: Modesto, C, et al.
Publicado: (2011)

The role of etanercept in juvenile dermatomyositis (JDMS) in children
por: Green, Katherine L, et al.
Publicado: (2014)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Etanercept efficacy in the treatment of chronic isolated inflammatory coxitis
por: Parodi, A, et al.
Publicado: (2008)

Long-term efficacy of etanercept in ADA2 deficiency
por: Caorsi, Roberta, et al.
Publicado: (2014)

Tumor necrosis factor alpha reverses the immunosuppressive properties of mesenchymal stem cells in collagen-induced arthritis
por: Djouad, F, et al.
Publicado: (2005)

PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis
por: Anink, J, et al.
Publicado: (2013)

Resistance of rheumatoid arthritis synovial fibroblasts to p38 MAP-kinase inhibition of pro-destructive functions mediated by tumor necrosis factor alpha/tumor necrosis factor receptor-1
por: Kunisch, E, et al.
Publicado: (2005)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Tumor necrosis factor alpha downregulates bone morphogenetic protein expression and matrix macromolecule synthesis in articular cartilage
por: Bobacz, K, et al.
Publicado: (2004)

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
por: Baraliakos, X, et al.
Publicado: (2005)

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Laminin, but not lipopolysaccharide, IL-1 or tumor necrosis factor alpha, induces IL-16 gene activity in synovial fibroblasts
por: Aicher, W, et al.
Publicado: (2003)

Tumor necrosis factor alpha induced proliferation of adult neural stem cells is mediated via NF-κB
por: Widera, Darius, et al.
Publicado: (2007)

Immunohistochemical study of tumor necrosis factor-alpha(TNF- α) expression in lung, liver, and spleen during aspergillosis infection
por: Dheeb, Batol Imran
Publicado: (2014)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
por: Sara, De Sanctis, et al.
Publicado: (2011)

DNase I levels and disease outcome in JIA patients treated with etanercept
por: Lazarević, D, et al.
Publicado: (2011)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

A case of chronic recurrent multifocal osteomyelýtýs successfully treated with etanercept
por: Aktay Ayaz, N, et al.
Publicado: (2008)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Etanercept therapy in JIA: impact on the need for intra-articular steroid injections
por: Pain, CE, et al.
Publicado: (2008)

Methotrexate, through adenosine release, downregulates tumor necrosis factor alpha-induced synovial fibroblast IL-15 expression and proliferation
por: Miranda, E, et al.
Publicado: (2005)

Tumor necrosis factor alpha modulates fibroblast-like synoviocyte expression of lymphangiogenesis-associated vascular endothelial growth factor C
por: Connor, AM, et al.
Publicado: (2004)

Moderate hypothermia during cardiopulmonary bypass reduces intramyocardial expression of tumor necrosis factor alpha via inhibition of AP-1
por: Ma, Q, et al.
Publicado: (2005)

Opioid receptor expression on neutrophils: effect of tumour necrosis factor alpha treatment
por: Schmidt, A, et al.
Publicado: (2007)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

Imaging of refractory chronic recurrent multifocal osteomyelitis succesfully treated with etanercept and methotrexate
por: Quesada-Masachs, Estefania, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lov4ikkuiu07phs7n4d1jtv398